A Prospective Multimodal Education Intervention for Providers Does Not Increase Hepatic Encephalopathy Treatment Rates
Digestive Diseases and Sciences · 2024
DOI: 10.1007/s10620-024-08445-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive Diseases and Sciences, 2024. Verfasst von Patrick A Twohig und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology & Hepatology, University of Nebraska Medical Center, 982000 Medical Center Drive, Omaha, NE, 68198-2000, USA. patwohig@g…. Hauptthemen laut MEDLINE: Hepatic Encephalopathy, Rifaximin. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Bausch Health.
Abstract (Originalsprache)
BACKGROUND: Over 50% of hospitalizations from hepatic encephalopathy (HE) are preventable, but patients often do not receive medical treatment. AIMS: To use a multimodal education intervention (MMEI) to increase HE treatment rates and to evaluate (1) trends in HE treatment, (2) predictors of receiving treatment, and (3) the impact of treatment on hospitalization outcomes. METHODS: Prospective single-center cohort study of patients hospitalized with HE from April 1, 2020-September 30, 2022. The first 15 months were a control ("pre-MMEI"), the subsequent 15 months (MMEI) included three phases: (1) prior authorization resources, (2) electronic order set, and (3) in-person provider education. Treatment included receiving any drug (lactulose or rifaximin), or combination therapy. Treatment rates pre- vs. post-MMEI were compared using logistic regression. RESULTS: 471 patients were included. There were lower odds of receiving any drug post-MMEI (p = 0.03). There was no difference in receiving combination therapy pre- or post-MMEI (p = 0.32). Predictors of receiving any drug included alcohol-related or cryptogenic cirrhosis (p's < 0.001), and the presence of ascites (p = 0.005) and/or portal hypertension (p = 0.003). The only significant predictor of not receiving any drug treatment was having autoimmune cirrhosis (p < 0.001). Patients seen by internal medicine (p = 0.01) or who were intoxicated (p = 0.02) were less likely to receive rifaximin. Any treatment was associated with higher 30-day liver disease-specific readmission (p < 0.001). CONCLUSION: This MMEI did not increase HE treatment rates, suggesting that alternative strategies are needed to identify and address barriers to treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology & Hepatology, University of Nebraska Medical Center, 982000 Medical Center Drive, Omaha, NE, 68198-2000, USA. patwohig@gmail.com.
- Division of Gastroenterology & Hepatology, University of Nebraska Medical Center, 982000 Medical Center Drive, Omaha, NE, 68198-2000, USA.
- Department of Biostatistics, University of Nebraska Medical Center, 984375 Nebraska Medical Center, Omaha, NE, 68198, USA.
- Departments of Internal Medicine & Hospital Medicine, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Förderung
- Bausch Health
Zitieren
APA
Twohig, P. A., Peeraphatdit, T. B., Samson, K., Schissel, M., Smith, L., Ashford, A., Freese, L., & McCashland, T. (2024). A Prospective Multimodal Education Intervention for Providers Does Not Increase Hepatic Encephalopathy Treatment Rates. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-024-08445-2
Vancouver
Twohig PA, Peeraphatdit TB, Samson K, Schissel M, Smith L, Ashford A, et al. A Prospective Multimodal Education Intervention for Providers Does Not Increase Hepatic Encephalopathy Treatment Rates. Digestive Diseases and Sciences. 2024. doi:10.1007/s10620-024-08445-2
BibTeX
@article{Twohig2024,
author = {Twohig, Patrick A and Peeraphatdit, Thoetchai Bee and Samson, Kaeli and Schissel, Makayla and Smith, Lynette and Ashford, Allison and Freese, Laura and McCashland, Timothy},
title = {A Prospective Multimodal Education Intervention for Providers Does Not Increase Hepatic Encephalopathy Treatment Rates},
journal = {Digestive Diseases and Sciences},
year = {2024},
doi = {10.1007/s10620-024-08445-2}
}
EUVIMED